Evidence map›Paper›PMID 41835238›Full record

ArticleChina CDC weekly2026

Impact of Hepatitis C Virus Co-infection on Antiretroviral Therapy Outcomes in Adults Living with HIV - China, 2002-2023.

Decai Zhao, Jingkun Hu, Yan Zhao, Xiumin Gan, Fan Lyu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in China CDC weekly, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Decai Zhao *National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
Jingkun Hu *Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.
Yan ZhaoNational Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
Xiumin GanNational Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
Fan LyuNational Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

What is already known about this topic?: The impact of hepatitis C virus (HCV) co-infection on antiretroviral therapy (ART) outcomes in people living with human immunodeficiency virus (HIV) remains controversial across studies. What is added by this report?: Using stratified matching methods, we constructed two cohorts - one with HIV/HCV co-infection and one with HIV mono-infection - to compare ART outcomes. Our analysis revealed that HIV/HCV co-infected individuals faced significantly elevated risks of mortality, virological failure, and attrition relative to their HIV mono-infected counterparts. What are the implications for public health practice?: Enhanced prevention, screening, and management (including treatment) of hepatitis C virus within people living with human immunodeficiency virus should be prioritized and strengthened as part of routine clinical care.

Indexed as

Antiretroviral therapyHepatitis C virusHuman immunodeficiency virus

Identifiers

PMID41835238
PMCPMC12983037

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.